ReviewPediatric gastroenterology, hepatology & nutrition2019
Clinical Aspects and Treatments for Pediatric Inflammatory Bowel Diseases.
Review in Pediatric gastroenterology, hepatology & nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review.Frontiers in pharmacology · 2026Pooled it
- Features and Outcomes of Inflammatory Bowel Disease among Filipino Children in a Tertiary Hospital: An Eleven-year Review.Acta medica Philippina · 2026Article
- Multiomics-Based Profiling of the Fecal Microbiome Reveals Potential Disease-Specific Signatures in Pediatric IBD (PIBD).Biomolecules · 2025Article
- Transitioning Pediatric Patients with Inflammatory Bowel Disease: Key Considerations for Adult Gastroenterologists.Pediatric gastroenterology, hepatology & nutrition · 2025Review
- Personalized Microbiome Modulation to Improve Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Multi-Omics and Interventional Approach.Microorganisms · 2025Article
- Early Surgical Resection in Pediatric Patients with Localized Ileo-Cecal Crohn's Disease: Results of a Retrospective Multicenter Study.Journal of clinical medicine · 2025Article
- Gut-microbiota-based ensemble model predicts prognosis of pediatric inflammatory bowel disease.iScience · 2024Article
- Real-World Outcomes of Dual Advanced Therapy in Children and Young Adults with Inflammatory Bowel Disease.Digestive diseases and sciences · 2024Article
- Infantile inflammatory bowel disease in three Syrian infants: a case series.Journal of medical case reports · 2024Article
- Transition is associated with lower disease activity, fewer relapses, better medication adherence, and lower lost-to-follow-up rate as opposed to self-transfer in pediatric-onset inflammatory bowel disease patients: results of a longitudinal, follow-up, controlled study.Therapeutic advances in gastroenterology · 2024Article
- Co-design and Consultation Ensure Consumer Needs Are Met: Building an eHealth Platform for Children with Inflammatory Bowel Disease.Digestive diseases and sciences · 2023Article
- Use of the Kono-S anastomosis in pediatric Crohn's disease: a single-institution experience.Pediatric surgery international · 2023Article
- Characteristics and Treatment Outcomes of Transition among Patients with Inflammatory Bowel Disease.Yonsei medical journal · 2023Article
- Atypical Immunoglobulin A Vasculitis in a Pediatric Patient With Ulcerative Colitis.ACG case reports journal · 2023Article
- Case Series of Precision Delivery of Methylprednisolone in Pediatric Inflammatory Bowel Disease: Feasibility, Clinical Outcomes, and Identification of a Vasculitic Transcriptional Program.Journal of clinical medicine · 2023Article
- A Review of Therapeutic Escalation for Pediatric Patients Admitted for Inflammatory Bowel Disease Flares.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- Gastrointestinal involvement in paediatric COVID-19 - from pathogenesis to clinical management: A comprehensive review.World journal of gastroenterology · 2021Review
- [How Can We Do Transition Successfully from Pediatric to Adult Clinics in Inflammatory Bowel Disease?]The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2021Review
- COVID-19 and pediatric inflammatory bowel disease: How to manage it?Clinics (Sao Paulo, Brazil) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of pediatric inflammatory bowel disease (IBD) is increasing worldwide, especially in the developing countries. It differs from adult disease in clinical manifestations, especially with regard to genetic predisposition in monogenic IBD. Pediatric disease also have a tendency to show more aggressive inflammation and greater extent of lesion. Newer drugs such as anti-tumor necrosis factor α have been known to make a difference in treating pediatric IBD. Recent studies suggested that the patients with high risk factors might have some benefits from earlier use of biologics. To achieve treatment goals such as relieving symptoms, optimizing growth, and improving quality of life while minimizing drug toxicity, more research is needed to develop tools for risk stratification in the use of biologics for pediatric IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.